Peptide library

Ozempic, Wegovy, Rybelsus

A GLP-1 receptor agonist approved for type 2 diabetes and, at higher doses, chronic weight management. It is the best-evidenced peptide in this library, backed by large randomised trials.

Mounjaro, Zepbound

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, with strong randomised-trial evidence.

Victoza, Saxenda

A daily GLP-1 receptor agonist approved for type 2 diabetes and weight management. Well evidenced but largely superseded by weekly agents.

Body Protection Compound 157

A synthetic fragment of a gastric protective protein and one of the most popular recovery peptides. Rodent studies consistently show accelerated healing of tendon, ligament, muscle and gut tissue — the basis for widespread community use — while human trials have yet to be completed.

TB4, Thymosin β4 fragment

A synthetic fragment of thymosin beta-4, a protein central to actin regulation and wound healing. Preclinical work supports the repair biology, which drives its popularity for injury recovery; published human data on the fragment itself are still early-stage.

Copper peptide, Glycyl-L-histidyl-L-lysine copper

A naturally occurring copper-binding tripeptide widely used in topical cosmetics, where it has the most support. Injectable use is anecdotal.

A selective growth-hormone secretagogue prized for its clean profile: it stimulates GH release with minimal effect on cortisol, prolactin or appetite, which is why it became a staple of GH-focused protocols. Formal outcome trials for physique and recovery goals haven't been run.

with DAC, Mod GRF (1-29)

A GHRH analogue that amplifies the body's natural GH pulses, classically paired with ipamorelin to hit both release pathways at once. Pharmacology studies show substantial, sustained GH and IGF-1 elevation, especially with the DAC variant; physique outcome trials are lacking.

GHRH (1-29)

A GHRH analogue with decades of clinical history — first as a diagnostic for GH deficiency, now widely prescribed through longevity and wellness clinics. Its GH-releasing effect in humans is well documented; modern anti-ageing outcome data are thinner.

Egrifta

A GHRH analogue approved to reduce excess abdominal fat in HIV-associated lipodystrophy. Off-label physique use is not supported by that approval.

Ibutamoren

An orally active ghrelin-receptor agonist that raises GH and IGF-1. Investigated in trials but not approved; popular for physique use.

MT-2, MT-II

A melanocortin-receptor agonist that reliably produces tanning with minimal UV, plus reported libido and appetite effects — it works, which is exactly why its risk profile matters. Documented adverse events (darkening moles, blood-pressure effects) and rapidly tightening legal status make it one of the highest-risk entries in this library.

Vyleesi, Bremelanotide

A melanocortin-receptor agonist approved as bremelanotide (Vyleesi) for premenopausal women with HSDD. Other uses are off-label.

Epitalon, AEDG

A synthetic tetrapeptide from the long-running Russian bioregulator programme, where decades of studies reported telomerase activation and improved survival in elderly cohorts. Those results are intriguing but come largely from one research group, without independent replication yet.

An ACTH-derived peptide with decades of clinical use in Russia for stroke recovery, cognitive complaints and attention, and a popular intranasal nootropic elsewhere. The independent, Western RCT base hasn't caught up with that regional clinical history.

A tuftsin-based peptide developed in Russia and used there clinically for anxiety — notable for reports of calm without sedation or dependence, which is what draws nootropic users. Like Semax, its regional clinical history outpaces independent Western trials.

Tα1, Zadaxin

An immunomodulatory peptide approved in several countries (e.g. as Zadaxin) for hepatitis and as a vaccine adjuvant. Approval status varies by region.

LY3437943

An investigational triple agonist (GIP/GLP-1/glucagon) with striking weight-loss results in phase 2 trials. Not yet approved; long-term safety is still being established.

AM833, part of CagriSema

An investigational long-acting amylin analogue, studied alone and combined with semaglutide (CagriSema). Not yet approved.

BI 456906

An investigational GLP-1/glucagon dual agonist in phase 3 development for obesity and liver disease. Not yet approved.

hGH fragment 176-191

The fat-loss fragment of human growth hormone, designed to trigger lipolysis without GH's growth and blood-sugar effects. It went through real human trials — a rarity in this category — which found it well tolerated but without meaningful weight loss, so the honest picture here is mixed.

The most potent of the classic growth-hormone-releasing peptides, with research interest extending to cardioprotective effects. Its trade-offs are known: it can raise cortisol/prolactin and receptors desensitise with continuous use, which shapes how the community cycles it.

Growth Hormone Releasing Peptide-6

One of the original growth-hormone-releasing peptides, distinctive for the strong hunger response that makes it popular in appetite- and mass-focused phases. GH release is its established effect; formal physique outcome trials haven't been run.

Pralmorelin

A growth-hormone-releasing peptide with genuine clinical pedigree — approved in Japan as the diagnostic agent pralmorelin. It releases more GH than GHRP-6 with less of the hunger effect, which is its niche in the community.

Long R3 IGF-1

A modified, long-acting form of IGF-1 — one of the most anabolic signalling molecules in the body — engineered to stay active far longer than the native hormone. That potency is the appeal in bodybuilding and also the risk: hypoglycaemia and indiscriminate tissue growth are real, and it is WADA-prohibited.

Mitochondrial ORF of the 12S rRNA-c

A mitochondrial-derived peptide that behaves like an exercise mimetic in rodent studies — improving insulin sensitivity, endurance and fat metabolism — with early human trials underway. One of the more scientifically interesting metabolic peptides.

A small-molecule NNMT inhibitor (not strictly a peptide) from academic obesity research, where it shrank fat cells and reduced weight in diet-induced obese mice without appetite suppression. Oral and popular in metabolic stacks; human trials haven't started.

Elamipretide, MTP-131

A mitochondria-targeting peptide in clinical development for mitochondrial and cardiac disease. Investigational; not approved.

Lysine-Proline-Valine

The anti-inflammatory business end of alpha-MSH, distilled to three amino acids. In cell and animal models — particularly colitis models — it damps inflammatory signalling, which is why gut-health protocols have adopted it; human trials are still to come.

Cathelicidin fragment

The body's own front-line antimicrobial peptide, with a large research literature on host defence and wound healing. Its biology is genuinely double-edged (context-dependent pro- and anti-inflammatory roles), and injectable product use runs ahead of the human trial base.

Delta Sleep-Inducing Peptide

A neuropeptide isolated from sleeping rabbits in the 1970s and studied for deep-sleep promotion and stress modulation. The original research era produced mixed results and modern trials never followed, so today's use rests on that early work plus community reports.

KP-10

The master switch of the reproductive axis, with genuine human research showing it drives LH, testosterone and sexual-response signalling — including studies of arousal pathways. Consumer libido products extrapolate from that research base.

GnRH

Synthetic gonadotropin-releasing hormone with established medical uses (diagnostics, fertility). Used off-label alongside TRT to maintain testicular function.

A hormone with established obstetric medical uses. Intranasal 'social' and wellbeing uses are researched but not approved for those purposes.

IBI362, LY3305677

A GLP-1/glucagon dual receptor agonist that was approved in China in 2025 for weight management. It remains investigational in most other regions.

LY3502970

An orally active, non-peptide (small-molecule) GLP-1 receptor agonist. It reported positive phase 3 results in 2025 and has been submitted for regulatory review; it is not yet approved for general use.

Melanotan I, Scenesse

An alpha-MSH analogue approved as Scenesse (a subcutaneous implant) to reduce phototoxicity in erythropoietic protoporphyria (EPP). It is the well-regulated cousin of the unapproved Melanotan II; approved use is narrow and clinician-administered.

Mechano Growth Factor, IGF-1Ec, Pegylated MGF

A pegylated form of mechano growth factor — the IGF-1 splice variant muscle produces in response to mechanical stress, which activates satellite cells for repair. That biology is real and well studied; product use in humans hasn't been trialled, and it is WADA-prohibited.

FS-344

A form of follistatin, the body's natural myostatin blocker. Gene-therapy and animal studies produced dramatic muscle growth — the famous 'double-muscled' phenotypes — which is the draw; whether an injected peptide product reproduces any of that in humans is untested, and it falls under WADA's myostatin-related prohibitions.

Aviptadil, Vasoactive Intestinal Polypeptide

A signalling peptide with broad anti-inflammatory and vasodilatory roles. Its synthetic form (aviptadil) has been investigated for lung conditions; intranasal VIP appears in off-label chronic-inflammatory (CIRS) protocols with limited formal evidence.

Thymus peptide extract

A thymus-derived peptide preparation used clinically in Russia and some neighbouring countries as an immunomodulator. Independent evidence outside that setting is limited.

HN, Mitochondrial-derived peptide

The first mitochondrial-derived peptide discovered, studied for protecting cells against stress-induced death, with human studies linking higher natural levels to longevity — centenarian families show elevated humanin. Supplementation itself hasn't been trialled.

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, PNB-0408

A small angiotensin IV–derived peptide from Alzheimer's research, reported in its originating lab to be orders of magnitude more potent than BDNF at driving new synapse formation in rodent models. Human studies haven't happened, and its growth-factor mechanism is the open safety question.

FPF-1070

A mixture of low-molecular-weight peptides and amino acids derived from pig brain, approved in a number of countries for stroke, dementia and traumatic brain injury. It is not approved in the US or UK, and trial results are mixed.

Glu-Asp-Arg, EDR peptide

A tripeptide from the same Russian bioregulator programme as epithalon, studied there for cognitive function and neuroprotection under oxidative stress. As with the rest of the programme, the interesting reported results await independent replication.

GSH, L-glutathione

The body's main intracellular antioxidant, a tripeptide of glutamate, cysteine and glycine. It has legitimate research and some clinical uses, but injectable use for skin-lightening is unproven and has drawn safety warnings from regulators.

Acetyl Hexapeptide-8, Acetyl Hexapeptide-3

A topical cosmetic peptide marketed as a needle-free alternative to botulinum toxin for expression lines. Its support is for topical cosmetic use; it is not an injectable and effects are modest.

FTPP, Prohibitin-targeting peptide

An experimental targeted peptide designed to kill the blood supply of fat tissue. It produced weight loss in obese primates but also caused kidney toxicity, and it has not progressed to approved human use.